Zobrazeno 1 - 10
of 15
pro vyhledávání: '"A. Wynter-Horton"'
Autor:
Haeseong Park, John Muth, Jan K Davidson-Moncada, Keun Wook Lee, Amy Sullivan, Stephen Reeder, Sarah Warren, Sarah E. Church, A. Wynter-Horton, Hope E. Uronis, Jayakumar Vadakekolathu, K. Huber, Y.-J. Bang, D. Li, Y-K Kang, Daniel V.T. Catenacci, Sergio Rutella, M.C.H. Ng, Peter C. Enzinger, Jan Baughman
Publikováno v:
Annals of Oncology. 30:v38-v39
Background Despite improvements in treatments, the 5-year survival of GEA patients (pts) is disappointing. Individual molecular subtypes display preferential responses to PD-1 blockade. M, an investigational Fc-optimized anti-HER2 monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42f41da095f0fb9e9b86fbf685d74a8f
https://doi.org/10.1093/annonc/mdz239.034
https://doi.org/10.1093/annonc/mdz239.034
Autor:
M. Rosales, Kian-Huat Lim, A. Wynter-Horton, K.-W. Lee, Y.-J. Bang, T. Wu, Jan Baughman, K. Huber, Haeseong Park, Philip J. Gold, Hope E. Uronis, Jan K Davidson-Moncada, Jill Lacy, Y-K. Kang, S.H. Park, Daniel Virgil Thomas Catenacci, M.C.H. Ng, Peter C. Enzinger, Jon M. Wigginton, J. Nordstrom
Publikováno v:
Annals of Oncology. 30:v484-v485
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b59b22375c9e2810aca705c5e4391c94
https://doi.org/10.1093/annonc/mdz253.014
https://doi.org/10.1093/annonc/mdz253.014
Autor:
Jennifer Yen, Paul A. Moore, Tony Wu, Yoon-Koo Kang, Keun Wook Lee, Jan Baughman, Francine Chen, Philip J. Gold, Matthew C.H. Ng, Jan K Davidson-Moncada, Aleksandra Franovic, Hope E. Uronis, Kian-Huat Lim, A. Wynter-Horton, Peter C. Enzinger, Se Hoon Park, Daniel V.T. Catenacci, Jill Lacy, Justin I. Odegaard, Yung-Jue Bang
Publikováno v:
Journal of Clinical Oncology. 37:65-65
65 Background: Trastuzumab (T) + chemo is standard first-line therapy (tx) for HER2+ gastroesophageal adenocarcinoma (GEA) pts, though progression ensues in 6-8 months. The approved second-line tx is ramucirumab +/- paclitaxel (R+PAC). Pts with GC ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c56fcd4f2d8d4d29d192a5ab7398ad7
https://doi.org/10.1200/jco.2019.37.4_suppl.65
https://doi.org/10.1200/jco.2019.37.4_suppl.65
Autor:
Daniel V.T. Catenacci, Jon M. Wigginton, Philip J. Gold, T. Wu, Hope E. Uronis, Keun Wook Lee, Haeseong Park, J. Yen, A. Wynter-Horton, Y.-J. Bang, Aleksandra Franovic, John Muth, Peter C. Enzinger, Jill Lacy, Justin I. Odegaard, Y-K. Kang, M.C.H. Ng, Sung-Ji Park, Jan Baughman, Jan K Davidson-Moncada
Publikováno v:
Annals of Oncology. 29:viii223
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52272505a5cdb2531ff005bb498c995e
https://doi.org/10.1093/annonc/mdy282.046
https://doi.org/10.1093/annonc/mdy282.046
Autor:
Hope E. Uronis, Daniel V.T. Catenacci, Peter C. Enzinger, Jill Lacy, Aleksandra Franovic, Daner Li, Keun Wook Lee, Matthew C.H. Ng, Se Hoon Park, Jan K Davidson-Moncada, Jan Baughman, A. Wynter-Horton, Haeseong Park, Yung-Jue Bang, Sam Hong, Philip J. Gold, Jennifer Yen, Yoon-Koo Kang, Ronan J. Kelly, John Muth
Publikováno v:
Journal of Clinical Oncology. 36:4030-4030
4030Background: T + chemo is standard 1st line therapy (tx) for HER2+ GEA patients (pts). However, pts typically progress within 6-8 months, with up to 30% demonstrating loss of HER2 positivity. No...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e044f17ad789e24d5d491e13b176ca7
https://doi.org/10.1200/jco.2018.36.15_suppl.4030
https://doi.org/10.1200/jco.2018.36.15_suppl.4030
Autor:
Catenacci, D.V. 1, Park, H. 2, Uronis, H. 3, Kang, Y.-K. 4, Ng, M.C.H. 5, Enzinger, P. 6, Lee, K.W. 7, Lim, K.H. 8, Gold, P.J. 9, Lacy, J. 10, Park, S.H. 11, Huber, K. 12, Wynter-Horton, A. 12, Nordstrom, J. 13, Wu, T. 14, Wigginton, J. 15, Baughman, J. 15, Rosales, M. 16, Davidson-Moncada, J. 15, Bang, Y.-J. 17
Publikováno v:
In Annals of Oncology October 2019 30 Supplement 5:v484-v485
Autor:
Rutella, S., Church, S.E., Vadakekolathu, J., Reeder, S., Sullivan, A.H., Warren, S., Baughman, J., Muth, J., Park, H., Uronis, H., Kang, Y.-K., Ng, M.C.H., Enzinger, P., Lee, K.W., Huber, K., Wynter-Horton, A., Li, D., Bang, Y.-J., Davidson-Moncada, J., Catenacci, D.V.
Publikováno v:
In Annals of Oncology October 2019 30 Supplement 5:v38-v39
Autor:
Catenacci, D.V.T., Park, H., Uronis, H.E., Kang, Y.-K., Ng, M., Gold, P., Lacy, J., Enzinger, P.C., Park, S., Lee, K.-W., Yen, J., Odegaard, J., Franovic, A., Baughman, J., Muth, J., Wynter-Horton, A., Wu, T., Wigginton, J., Davidson-Moncada, J.K., Bang, Y.-J.
Publikováno v:
In Annals of Oncology October 2018 29 Supplement 8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.